Yohei Urata
Overview
Explore the profile of Yohei Urata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaino M, Kaino S, Goma W, Hideura E, Hitosugi T, Harima Y, et al.
Clin J Gastroenterol
. 2020 Jul;
14(1):297-303.
PMID: 32643120
A 72-year-old man with obstructive jaundice, diagnosed with distal biliary carcinoma, underwent pylorus-preserving pancreaticoduodenectomy. The patient was histopathologically and immunohistochemically diagnosed with mixed neuroendocrine non-neuroendocrine neoplasm. Pathological examination revealed that...
2.
Saeki I, Yamasaki T, Yamashita S, Hanazono T, Urata Y, Furutani T, et al.
Cancers (Basel)
. 2020 Mar;
12(4).
PMID: 32218295
There are limited reports regarding early predictors of objective response (OR) in patients with hepatocellular carcinoma (HCC) treated with lenvatinib. This retrospective study including 70 patients aimed to investigate the...
3.
Urata Y, Yamasaki T, Saeki I, Iwai S, Kitahara M, Sawai Y, et al.
Hepatol Res
. 2015 Aug;
46(5):434-42.
PMID: 26288059
Aim: Alcoholic hepatocellular carcinoma (ALD-HCC) accounts for the majority of non-B non-C HCC (NBNC-HCC) cases. Although alcohol is a potent carcinogen, there have been few reports on the influence of...
4.
Saeki I, Yamasaki T, Tanabe N, Iwamoto T, Matsumoto T, Urata Y, et al.
PLoS One
. 2015 May;
10(5):e0126649.
PMID: 25992784
Background & Aims: Hepatic arterial infusion chemotherapy (HAIC) is an option for treating advanced hepatocellular carcinoma (HCC). Because of the poor prognosis in HAIC non-responders, it is important to identify...
5.
Marumoto M, Yamasaki T, Marumoto Y, Saeki I, Harima Y, Urata Y, et al.
Hepatogastroenterology
. 2014 Jun;
61(129):162-7.
PMID: 24895814
Background/aims: Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis and usually presents as advanced disease. Hepatic arterial infusion chemotherapy (HAIC) is a promising option for advanced hepatocellular carcinoma; however, there have...
6.
Terai S, Takami T, Yamamoto N, Fujisawa K, Ishikawa T, Urata Y, et al.
Tissue Eng Part B Rev
. 2014 Jan;
20(3):206-10.
PMID: 24450831
In 2003, we started autologous bone marrow cell infusion (ABMi) therapy for treating liver cirrhosis. ABMi therapy uses 400 mL of autologous bone marrow obtained under general anesthesia and infused...
7.
Oono T, Yamasaki T, Zaitsu J, Saeki I, Iwamoto T, Harima Y, et al.
Hepatol Res
. 2013 Aug;
44(10):E54-62.
PMID: 23905687
Aim: Insulin resistance (IR) increases during the early stages of hepatitis C virus (HCV)-related chronic liver disease and is a sign of poor prognosis as well as a risk factor...
8.
Zaitsu J, Yamasaki T, Saeki I, Harima Y, Iwamoto T, Harima Y, et al.
Hepatol Res
. 2013 Apr;
44(5):481-90.
PMID: 23607437
Aim: We recently reported that the iron chelator deferoxamine (DFO) is efficacious in advanced hepatocellular carcinoma (HCC) patients. Iron regulation may thus have an important impact in HCC therapy. Because...
9.
Terai S, Tanimoto H, Maeda M, Zaitsu J, Hisanaga T, Iwamoto T, et al.
J Gastroenterol
. 2012 Apr;
47(5):491-7.
PMID: 22488349
Liver cirrhosis patients generally progress to liver failure. To cure this progressive disease, we developed a novel cell therapy using bone marrow cells; autologous bone marrow cell infusion (ABMi) therapy....
10.
Yamasaki T, Saeki I, Harima Y, Zaitsu J, Maeda M, Tanimoto H, et al.
J Gastroenterol
. 2012 Feb;
47(6):715-22.
PMID: 22322658
Background: Transcatheter arterial infusion chemotherapy (TAI) using a combination of iodized oil (lipiodol) and degradable starch microspheres (DSMs) has been reported to be superior to TAI with either lipiodol or...